These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

597 related items for PubMed ID: 28797783

  • 1. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
    Bhamidipati PK, Fiala MA, Grossman BJ, DiPersio JF, Stockerl-Goldstein K, Gao F, Uy GL, Westervelt P, Schroeder MA, Cashen AF, Abboud CN, Vij R.
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783
    [Abstract] [Full Text] [Related]

  • 2. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.
    Elayan MM, Horowitz JG, Magraner JM, Shaughnessy PJ, Bachier C.
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1921-5. PubMed ID: 26033279
    [Abstract] [Full Text] [Related]

  • 3. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW, Helmons PJ, Belew H, Lane JR, Ball ED.
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
    Stewart DA, Smith C, MacFarland R, Calandra G.
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
    [Abstract] [Full Text] [Related]

  • 5. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S, Karakus E, Kaynar L, Kurnaz F, Pala C, Keklik M, Zararsiz G, Solmaz M, Eser B, Cetin M, Unal A.
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [Abstract] [Full Text] [Related]

  • 6. Tbo-filgrastim versus filgrastim for stem cell mobilization and engraftment in autologous hematopoietic stem cell transplant patients: A retrospective review.
    Potter A, Beck B, Ngorsuraches S.
    J Oncol Pharm Pract; 2020 Jan; 26(1):23-28. PubMed ID: 30854925
    [Abstract] [Full Text] [Related]

  • 7. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M, Silva M.
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study.
    Matsue K, Kumagai K, Sugiura I, Ishikawa T, Igarashi T, Sato T, Uchiyama M, Miyamoto T, Ono T, Ueda Y, Kiguchi T, Sunaga Y, Sasaki T, Suzuki K.
    Int J Hematol; 2018 Nov; 108(5):524-534. PubMed ID: 30043330
    [Abstract] [Full Text] [Related]

  • 11. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
    Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G.
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
    Danylesko I, Sareli R, Bloom-Varda N, Yerushalmi R, Shem-Tov N, Shimoni A, Nagler A.
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
    [Abstract] [Full Text] [Related]

  • 14. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
    Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, Dehner C, Gibney C, Bridger G, Calandra G.
    Bone Marrow Transplant; 2010 Jan; 45(1):39-47. PubMed ID: 19483760
    [Abstract] [Full Text] [Related]

  • 15. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
    Micallef IN, Stiff PJ, Nademanee AP, Maziarz RT, Horwitz ME, Stadtmauer EA, Kaufman JL, McCarty JM, Vargo R, Cheverton PD, Struijs M, Bolwell B, DiPersio JF.
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1187-1195. PubMed ID: 29410180
    [Abstract] [Full Text] [Related]

  • 16. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ.
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study.
    Gutiérrez-Aguirre CH, Alvarado-Navarro DM, Palomares-Leal A, Mejía-Jaramillo G, Salazar-Riojas R, León AG, Colunga-Pedraza PR, Sotomayor-Duque G, Jaime-Pérez JC, Cantú-Rodríguez OG, Del Carmen Tarín-Arzaga L, Flores-Jiménez JA, Gómez-Almaguer D.
    Transfusion; 2019 Dec; 59(12):3721-3726. PubMed ID: 31618456
    [Abstract] [Full Text] [Related]

  • 20. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, Namberger K, Witt V, Schloegl E, Zojer N, Linkesch W, Kalhs P, Greinix HT.
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.